.webp)
In the competitive landscape of bioconjugates, speed-to-clinic is critical. However, the complex nature of these therapies can create roadblocks and delays, making it hard for developers to keep pace.
We designed ADCelerate™ to provide our partners with a resolution – combining the strength of our global network to offer our partners a single pathway to market. By aligning the strength and capabilities across our global network, ADCelerate delivers a single, streamlined pathway from early R&D through IND-enabling development and GMP clinical supply.
By consolidating these activities into a single, unified structure, we help partners mitigate risk, reduce costs, and accelerate timelines. Leveraging this model, we guarantee the delivery of bioconjugate drug substance and drug product at a fixed price in as fast as 12 months, supporting our partners as they move throughout and beyond phase I development.
Since its launch in 2020, ADCelerate has empowered us to develop hundreds of unique conjugates, complete thousands of ADC batches, and manufacture several commercial bioconjugates.
Global Technical Lead, Peptides
VP & Global Head of Bioconjugate and Large Molecule R&D
VP & Global API Technical Lead
Co-Founder & Chief Operating Officer of Yapan Bio, a Piramal Pharma Ltd. Associate Company
VP & Global Head of Formulations R&D
Director of Development, Lexington Sterile Injectables Facility
-1.png)
.png)
.png)
.webp)
